CAR T-Cell Therapies for Multiple Myeloma

Neurotoxicities can be monitored long term with personalized questions, according to Mary Steinbach, DNP, APRN.

Treatment access can still affect patients in urban communities, said Mary Steinbach, DNP, APRN.

CAR T-cell therapy is starting to enter treatment conversations sooner with patients with multiple myeloma, according to Nick Barkemeyer, PA-C, MMS.

At a recent Community Case Forum, an expert discussed the risk of cytokine release syndrome after patients undergo CAR T-cell therapy.

Daniel Verina, DNP, ACNP-BC, discussed how CAR T-cell therapy is changing the treatment landscape for patients with multiple myeloma.